JPMorgan Boosts Target on Human Genome (HGSI) to $35
More News related to HGSI
- Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
- Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
- Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
More News related to Analyst Comments
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
Following yesterday's news that BENLYSTA met its primary endpoint in a second Phase 3 trial, and the resulting 35% spike in the stock, JPMorgan has raised its price target on shares of Human Genome Sciences (Nasdaq: HGSI) from $25 to $35. The firm maintains its Overweight rating.
The stock is continuing higher today, currently up about 1% to $25.53. JPMorgan's new price target represents potential upside of about 37%.
To see all the analyst calls on shares of Human Genome, including a price target raise at Goldman, visit our Analyst Ratings page.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States.
Related Categories
Analyst CommentsStocks Mentioned
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
